It has been demonstrated that in HR+ breast cancer patients, the level of monocytic and polymorphonuclear myeloid-derived suppressor cells (MDSCs) in peripheral blood are reduced after treatment with different CDK4/6is [77]. This evidence concerns the gene CDK4 and breast cancer.